NCT05243550 2024-11-04ENVISIONUroGen Pharma Ltd.Phase 3 Active not recruiting240 enrolled 20 charts 1 FDA
NCT06462001 2024-06-17BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder CancerNottingham University Hospitals NHS TrustPhase 3 Active not recruiting500 enrolled